Benjamin Hebraud
Toulouse, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 34 publications
A dexamethasone-free daratumumab-ixazomib regimen in frail elderly patients with relapsed or refractory multiple myeloma: Results of the IFM 2018-02 phase II study.
Journal: British journal of haematology
Published: January 28, 2026
Outpatient Rescue With Stem Cells Boost for Refractory Hematotoxicity Following anti-BCMA CAR T-Cell Therapy: A Case Report.
Journal: Case reports in hematology
Published: October 13, 2025
Comparison of Patient-Reported Outcomes for Elranatamab in MagnetisMM-3 Versus Real-World Physician Choice of Therapy for Triple-Class Refractory Multiple Myeloma.
Journal: Clinical lymphoma, myeloma & leukemia
Published: August 25, 2025
Real-World Evidence Supports Venetoclax as an Additional Option for Patients With t(11;14) Myeloma.
Journal: Clinical lymphoma, myeloma & leukemia
Published: March 26, 2025
Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma.
Journal: Frontiers in oncology
Published: March 30, 2023
Non-interventional Study Evaluating the Mobilization of Stem Cells by Plerixafor Before Salvage Autologous Stem Cell Transplant in Relapsed Multiple Myeloma (IFM-2015-03).
Journal: Clinical hematology international
Published: November 01, 2022
Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA.
Journal: Leukemia
Published: July 01, 2021
Up-front carfilzomib, lenalidomide, and dexamethasone with transplant for patients with multiple myeloma: the IFM KRd final results.
Journal: Blood
Published: January 07, 2021
Last Updated: 09/26/2026